The Safety of Anticoagulation Therapy in Liver Cirrhosis Portal Vein Thrombosis and Its Impact on Hospital Outcomes.

The Safety of Anticoagulation Therapy in Liver Cirrhosis Portal Vein Thrombosis and Its Impact on Hospital Outcomes.

"The Hepatology Digest -Liver Vascular Disease Column" is an academic section jointly initiated by Dr. Xingshun Qi of the Department of Gastroenterology, Northern Theater General Hospital, at the invitation of the Hepatology Digest editorial team. It regularly collects and discusses the latest research in the field of liver vascular diseases. Every two weeks, on Wednesdays, it features an in-depth discussion of a significant publication, aiming to enlighten readers about the rationale behind these findings and inspire clinical research and practical application.

The Treatment and Clinical Cure of Childhood Hepatitis B

China is a country with a high incidence of hepatitis B, and mother-to-child transmission is an important route for children in China to contract the hepatitis B virus (HBV). Although chronic HBV infection in childhood rarely progresses to active hepatitis, there is still a risk of developing cirrhosis and liver cancer. Therefore, understanding the epidemiological characteristics of childhood hepatitis B and taking effective prevention and control measures are particularly important to reduce the incidence of childhood hepatitis B in China and promote healthy growth. In recent years, as the goal of clinical cure for hepatitis B has gradually gained more attention, the issue of clinical cure for childhood hepatitis B has also received increasing focus. At the recently concluded "15th Academic Conference on Antiviral Therapy Difficulties and Hotspots in Chronic Viral Hepatitis," Dr. Fusheng Wang from the Fifth Medical Center of the PLA General Hospital presented a special report on "Treatment and Clinical Cure of Childhood Hepatitis B," offering an in-depth analysis of these issues.
Strategies to Optimize CAR-T Cell Therapy in Hematological Malignancies: Chinese Experience

Strategies to Optimize CAR-T Cell Therapy in Hematological Malignancies: Chinese Experience

🩸 Advancements in Hematological Malignancies: Professor Xiaojun Huang's Insights on CAR-T Cell Therapy In the landscape of oncology, hematological malignancies cast a formidable shadow, spanning leukemia, lymphoma, and multiple myeloma. Yet, amidst these intricate conditions, a beacon of hope emerges through the transformative strides of CAR-T cell therapy. This groundbreaking approach stands as a promising avenue in combatting these complex diseases. Notably, China, under the guidance of esteemed scholars like Professor Xiaojun Huang, leads the charge, revolutionizing CAR-T cell therapy within the realm of hematological malignancies. Recently featured in the esteemed Journal of Hematology, Professor Huang's team unveiled their seminal work titled "Strategies to optimize CAR-T cell therapy in hematological malignancies: Chinese experience." This comprehensive study offers meticulous insights into the progress, challenges, and pivotal contributions within hematological malignancy research, positioning China at the forefront of this cutting-edge field. Join us as we delve into the transformative insights presented by Professor Xiaojun Huang's team, exploring the evolution and impactful strides in CAR-T cell therapy for hematological malignancies within the Chinese landscape.
Hematopoietic Stem Cell Transplantation Activity in China 2020-2021 During the SARS-CoV-2 Pandemic

Hematopoietic Stem Cell Transplantation Activity in China 2020-2021 During the SARS-CoV-2 Pandemic

🩸 Resilience Amidst Crisis: Prof. Xiaojun Huang's Pioneering Insights on HSCT during COVID-19 In a world disrupted by the SARS-CoV-2 pandemic, the adaptability and innovation of medical practices became imperative. An illuminating study, recently unveiled in Transplantation and Cellular Therapy's February 2023 publication, sheds light on a beacon of hope amidst this chaos. Titled "Hematopoietic stem cell transplantation activity in China 2020-2021 during the SARS-CoV-2 pandemic: a report from the Chinese Blood and Marrow Transplantation Registry Group," this groundbreaking research stands as a testament to the resilience and innovation witnessed in China's healthcare landscape during unprecedented global health challenges. Led by the esteemed Prof. Xiaojun Huang and his proficient team of experts, this study delves into the adaptability of hematopoietic stem cell transplantation (HSCT) within China, offering invaluable insights into its navigation through the complexities of the COVID-19 era. Prof. Huang's leadership underscores a dedication to excellence, illuminating pioneering pathways in healthcare resilience
Professor Xiaojun Huang ‘s Team Reveals New Mechanism of Injury to Bone Marrow Endothelial Progenitor Cells and Proposes Targeted Repair Strategies

Professor Xiaojun Huang ‘s Team Reveals New Mechanism of Injury to Bone Marrow Endothelial Progenitor Cells and Proposes Targeted Repair Strategies

🩸 Professor Xiaojun Huang and Team: Illuminating Hope in Blood Health Meet the unsung heroes—Professor Xiaojun Huang and their dedicated team—who've ventured into the labyrinth of blood health, uncovering a profound truth within our marrow's tapestry. They've unraveled a poignant narrative—a disruption in glycolysis, a hidden force causing turmoil for endothelial progenitor cells (EPCs). This upheaval imperils the delicate dance of hematopoiesis, the heartbeat of our blood's resilience. Backed by national R&D programs and the unwavering support of the National Natural Science Foundation, their discovery isn't just science; it's a lifeline for those navigating the storm of chemotherapy, radiotherapy, and stem cell transplants. Picture the impact—precision treatments targeting this anomaly, preserving the marrow's sanctity amid the chaos of treatments, kindling hope for countless souls. Their tale echoed at prestigious gatherings—the 24th European Hematology Association Congress (EHA) and the 48th European Society for Blood and Marrow Transplantation Congress (EBMT)—etched in Haematologica journal's pages.
CDM Monthly Review (November 2023, Issue 75)

CDM Monthly Review (November 2023, Issue 75)

Hello experts and colleagues, in this 75th issue of the CDM Monthly Review for November 2023, we share six recent publications in the field of portal hypertension diagnosis and treatment (three on diagnosis and monitoring, and three on multidisciplinary treatment). This issue features guest experts: Dr. Bingtian Dong from the Department of Ultrasound at the First Affiliated Hospital of Anhui Medical University, Dr.Ningning Wang from the Department of Gastroenterology at the First Affiliated Hospital of China Medical University, Dr.Lei Zheng from the Department of General Surgery at the Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine, and Dr. Sheng Wang from the Department of Gastroenterology at the Third Affiliated Hospital of Sun Yat-sen University.

Application of Ultrasound Elastography Scoring in Diagnosing Potential Porto-Sinusoidal Vascular Disease in Patients with Portal Vein Thrombosis

The "Hepatology Digest-Vascular Liver Disease Column" is an academic column jointly initiated by Dr. Xingshun Qi of the Department of Gastroenterology, Northern Theater Command General Hospital, at the invitation of the editorial department of " Hepatology Digest". This column regularly collects and organizes research progress in the field of vascular liver disease. Every two weeks (on Wednesday), an important piece of literature is selected for in-depth discussion. The aim is to help readers understand the rationale behind these advancements and to inspire clinical and scientific thinking, putting knowledge into practice.
Construction and Validation of a Hepatocellular Carcinoma Prognosis Model Based on Stress Granules

Construction and Validation of a Hepatocellular Carcinoma Prognosis Model Based on Stress Granules

In an effort to keep clinicians and researchers in the field of hepatology abreast of the latest academic knowledge and research trends, " Hepatology Digest " has collaborated with the "Journal of Clinical and Translational Hepatology" (JCTH) to introduce the "Journal Co-Read" section. Each week, this section selects and interprets highlights from a key publication, summarizing its main points in the hope of enhancing clinical diagnostic and treatment levels, inspiring research thinking, and improving writing skills.

Efficacy Analysis of “T+A” Therapy in Different Treatment Populations of HCC

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Most patients are unable to undergo surgical resection at the time of diagnosis, making systemic therapy an important treatment approach for this group. The combination immunotherapy of Atezolizumab plus Bevacizumab (“T+A”) has become the new first-line standard treatment for unresectable HCC patients due to its significant improvement in overall survival (OS) compared to sorafenib. However, its effectiveness in different populations, including HCC patients with different etiologies, Child-Pugh B grade HCC, and intermediate-stage HCC beyond the up-to-seven criteria, remains unclear. The journal "Hepatology Digest" has reviewed recent studies on this topic for the benefit of readers.